Efficacy of trilostane for the treatment of equine Cushing's syndrome.
Trilostane, a competitive 3-beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism. Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety. Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4-1 mg/kg (mean 0.5 mg/kg) trilostane once daily. Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 +/- 53.0 nmol/l) and after (130 +/- 46.1 nmol/l) trilostane. Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration. Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted.